Targeting HER 2 and angiogenesis in gastric cancer. Issue 1 (2nd January 2016)

• Record Type: Journal Article
• Authors: Jomrich, G; Schoppmann, SF
• Is Part Of: Expert review of anticancer therapy. Volume 16:Issue 1(2016)
• Page Start: 111
• Page End: 122
• Publication Date: 2016-01-02
• Subjects: HER2 -- VEGF -- angiogenesis -- gastric cancer -- targeted therapy -- trastuzumab -- ramucirumab -- chemo resistance; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/14737140.2016.1121110
• Languages: English
• ISSNs: 1473-7140

Abstract

Abstract : Gastric cancer is one of the most commonly diagnosed and the second leading cause of cancer death worldwide. Surgery combined with multimodal therapy remains the only curative therapy. However, local relapse or distant metastases occur in more than 50% of radically resected patients. Due to molecular therapies, targeting HER2 and angiogenesis, major advances in the treatment of gastric cancer could be achieved. Nevertheless, development of resistance to monoclonal antibodies, such as trastuzumab, is arising. Currently a number of promising new therapeutic are under investigation, combining chemotherapy with newly developed agents to overcome cancer resistance. In this review we report current clinical applications of targeted therapies and overview ongoing trials, investigating the use of monoclonal antibodies in (HER2 positive) gastric cancer.